Andrea E. Doak - Concepedia

Author

Andrea E. Doak

Also Known As

Andrea Doak, Andrea E. Doak, Doak, Andrea E.

Publications

444

Citations

H-Index

Concepts

All Affiliations

Andrea E. Doak is an author at University of Colorado Denver specializing in cancer genetics, medicine, and cancer therapeutics.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	20
2	Cell Biology	1	1	20
3	Pathology	1	1	20
4	Pharmacology	1	1	20
5	Cancer Cell Biology	1	1	20

Andrea E. Doak

Publications

442

Citations

H-Index

Page 1

	Year	Citations
Resistance Mechanisms to Targeted Therapies in <i>ROS1</i> + and <i>ALK</i> + Non–small Cell Lung Cancer Caroline E. McCoach, Anh T. Le, Katherine Gowan, Clinical Cancer Research	2018	240
Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling Sarah K. Nelson-Taylor, Anh T. Le, Minjae Yoo, Molecular Cancer Therapeutics	2017	78
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes Adriana Estrada‐Bernal, Anh T. Le, Andrea E. Doak, Clinical Cancer Research	2020	77
Abstract A157: Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions Adriana Estrada‐Bernal, Andrea E. Doak, Anh T. Le, Molecular Cancer Therapeutics Antitumor ActivityPathologyHypoxia-activated Egfr TkiCancer BiologyTumor Biology	2018	20
Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death Joshua M. Marcus, Russell T. Burke, Andrea E. Doak, Cell Cycle	2018	17
Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling Laura Schubert, Anh T. Le, Adriana Estrada‐Bernal, Molecular Pharmacology	2021	10

Page 1